| PROJECT | CENTERS / COUNTRIES | WEST EUROPE | EST EUROPE | LATIN AMERICA | NORTH AMERICA | OTHERS | TOTALS |
| PAPA-Can | 2 / 1 | 3 | 0 | 0 | 0 | 0 | 3 |
| CEST | 2 / 1 | 33 | 0 | 0 | 0 | 0 | 33 |
| Kawasaki Disease IVIg resistance scores | 19 / 9 | 499 | 14 | 15 | 0 | 215 | 743 |
| HyperPED-COVID | 55 / 22 | 460 | 215 | 170 | 0 | 164 | 1009 |
| LoSQI validation | 25 / 17 | 124 | 25 | 16 | 0 | 24 | 189 |
| DAISY | 10 / 9 | 59 | 43 | 0 | 0 | 0 | 102 |
| The STARS trial | 20 / 1 | 240 | 0 | 0 | 0 | 0 | 240 |
| JIA classification | 97 / 32 | 920 | 379 | 36 | 103 | 81 | 1519 |
| INSAID registry | 3 / 3 | 31 | 0 | 0 | 0 | 0 | 31 |
| MAS | 90 / 31 | 620 | 138 | 74 | 148 | 131 | 1111 |
| ABIRISK Registry | 24 / 12 | 69 | 86 | 0 | 0 | 0 | 155 |
| EUROFEVER | 127 / 42 | 4799 | 794 | 73 | 16 | 361 | 6043 |
| PHARMACHILD | 86 / 31 | 5357 | 2882 | 791 | 0 | 275 | 9305 |
| EPOCA | 118 / 49 | 5517 | 4036 | 1313 | 773 | 2175 | 13814 |
| JDM Trial | 53 / 20 | 86 | 12 | 34 | 6 | 0 | 138 |
| MTX Withdrawal | 61 / 29 | 178 | 93 | 80 | 0 | 13 | 364 |
| Vasculitis | 93 / 36 | 916 | 159 | 233 | 6 | 85 | 1399 |
| Antares | 16 / 1 | 213 | 0 | 0 | 0 | 0 | 213 |
| CSA | 56 / 22 | 183 | 50 | 25 | 85 | 1 | 344 |
| JDM CS | 95 / 36 | 160 | 37 | 78 | 17 | 3 | 295 |
| JSLE CS | 108 / 39 | 258 | 93 | 150 | 35 | 21 | 557 |
| CHAQ CHQ Healthy | 32 / 32 | 2115 | 575 | 524 | 0 | 195 | 3409 |
| CHAQ CHQ JIA | 32 / 32 | 2019 | 696 | 379 | 0 | 141 | 3235 |
| MTX Pavia | 56 / 20 | 518 | 39 | 66 | 8 | 2 | 633 |
| TOTAL | 236 / 54 | 25377 | 10366 | 4057 | 1197 | 3887 | 44884 |